CRL Charles River Laboratories International, Inc.

327.93USD-1.60%Mkt Cap: 15.71B USDP/E: 356.45

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Mode…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap15.71B USD
Enterprise Value18.41B USD
Revenue (TTM)3.98B USD
Gross Profit1.32B USD
Net Income (TTM)-144.34M USD
Revenue/Share82.00 USD
Last Price327.93 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees18.3K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)356.45
P/E (Forward)25.28
PEG0.12
EV/EBITDA20.25
EV/Revenue4.63
P/S3.95
P/B4.87
EPS (TTM)0.92 USD
EPS (Forward)12.97 USD
52W Range
146.2078% of range379.63
52W High379.63 USD
52W Low146.20 USD
Profitability
Gross Margin32.96%
Oper. Margin14.27%
EBITDA Margin22.87%
Profit Margin-3.59%
ROE-4.56%
ROA-2.02%
ROIC7.20%
ROCE6.67%
Growth
Revenue Growth-2.20%
Earnings Growth523.60%
Cash Flow & Leverage
Operating CF737.65M USD
CapEx (TTM)219.15M USD
FCF Margin11.15%
FCF Yield2.82%
Net Debt2.65B USD
Net Debt/EBITDA2.92
Net Debt/FCF5.98
Balance Sheet
Debt/Equity0.81
Current Ratio1.41
Quick Ratio0.86
Book Value/Sh67.40 USD
Cash/Share4.18 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)350.57 USD
Upside (mean)+6.9%
Target Range145.00 USD – 400.00 USD
145.00+6.9% to mean400.00
# Analysts14
Ownership
Shares Out.47.92M
Float47.42M
Insiders0.47%
Institutions113.61%
Short Interest
Short Ratio2.6d
Short % Float7.20%
Short % Out.6.23%
Shares Short2.99M
Short (prev mo.)2.88M
Technical
SMA 50314.13 (+4.4%)
SMA 200229.59 (+42.8%)
Beta1.34
S&P 52W Chg12.00%
Avg Vol (30d)1.08M
Avg Vol (10d)897.51K
Technical Indicators
RSI (14)48.1
MACD4.0226
MACD Signal7.7039
MACD Hist.-3.6812
BB Upper375.82 USD
BB Middle344.38 USD
BB Lower312.95 USD
BB Width18.26%
ATR (14)15.04 USD
Vol Ratio (20d)0.43x

About Charles River Laboratories International (NYSE: CRL)

›

Charles River Laboratories International (NYSE: CRL) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 18,300 employees.

The shares were at 327.93 USD on 19 November 2026, up 95.4% over 52 weeks. Its 52-week range is 146.20 USD to 379.63 USD: the price is 13.6% below the high and 124.3% above the low.

At a market capitalisation of 15.71B USD, it trades at 356.4 times trailing earnings and 25.3 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 34.9, a premium of 922% for CRL.

Charles River Laboratories International reports return on equity of -4.6%, an operating margin of 14.3% and revenue down 2.2% year over year.

Its debt exceeds its cash by 2.65B USD, a debt-to-equity ratio of 0.81. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 350.57 USD is 6.9% above the current price. The next earnings report is expected on 17 February 2027.